Lipella pharmaceuticals announces u.s. patent allowance for innovative liposomal drug delivery platform

Pittsburgh, pa, october 15, 2024 – prism mediawire – lipella pharmaceuticals inc. (nasdaq: lipo), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the u.s. patent and trademark office (uspto) for its proprietary liposomal drug delivery platform.
LIPO Ratings Summary
LIPO Quant Ranking